AAA
ENGN icon

Affinity Asset Advisors’s enGene Therapeutics ENGN Stock Holding History

Affinity Asset Advisors’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.16M Sell
610,370
-33,000
-5% -$294K 0.21% 78
2025
Q4 		$5.81M Buy
643,370
+566,370
+736% +$4.54M 0.33% 60
2025
Q3 		$526K Hold
77,000
– – 0.05% 89
2025
Q2 		$280K Buy
+77,000
New +$289K 0.04% 81

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Affinity Asset Advisors's ENGN Position: Q1 2026 in Review

Affinity Asset Advisors reduced its enGene Therapeutics (ENGN) stake by 5.1% in Q1 2026, selling an estimated $294K and leaving 610,370 shares worth $4.16M. The position accounts for 0.21% of the portfolio, ranked #78.

Affinity Asset Advisors first reported a position in ENGN in Q2 2025 and has held it in 4 quarters since. The position peaked at $5.81M in Q4 2025. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Affinity Asset Advisors held 610,370 shares of enGene Therapeutics worth $4.16M as of Q1 2026.
  • Affinity Asset Advisors sold 33,000 enGene Therapeutics shares in Q1 2026, an estimated $294K.
  • enGene Therapeutics made up 0.21% of Affinity Asset Advisors's portfolio in Q1 2026, its #78 holding.
  • Affinity Asset Advisors first reported a position in enGene Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Affinity Asset Advisors's enGene Therapeutics position peaked at $5.81M in Q4 2025.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.